Ana I Robles1, Giovanni Traverso2, Ming Zhang3, Nicholas J Roberts4, Mohammed A Khan1, Christine Joseph3, Gregory Y Lauwers5, Florin M Selaru6, Maria Popoli3, Meredith E Pittman7, Xiquan Ke6, Ralph H Hruban7, Stephen J Meltzer6, Kenneth W Kinzler8, Bert Vogelstein9, Curtis C Harris10, Nickolas Papadopoulos11. 1. Laboratory of Human Carcinogenesis, National Cancer Institute's Center for Cancer Research, National Institutes of Health, Bethesda, Maryland. 2. Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Department of Chemical Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts. 3. Ludwig Center at Johns Hopkins, Baltimore, Maryland. 4. Ludwig Center at Johns Hopkins, Baltimore, Maryland; Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 6. Division of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 7. Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland. 8. Ludwig Center at Johns Hopkins, Baltimore, Maryland; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 9. Ludwig Center at Johns Hopkins, Baltimore, Maryland; Howard Hughes Medical Institute, Chevy Chase, Maryland; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: bertvog@gmail.com. 10. Laboratory of Human Carcinogenesis, National Cancer Institute's Center for Cancer Research, National Institutes of Health, Bethesda, Maryland. Electronic address: harrisc@mail.nih.gov. 11. Ludwig Center at Johns Hopkins, Baltimore, Maryland; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: npapado1@jhmi.edu.
Abstract
BACKGROUND & AIMS: A long duration of inflammatory bowel disease (IBD) increases the risk for colorectal cancer. Mutation analysis of limited numbers of genes has indicated that colorectal tumors that develop in patients with IBD differ from those of patients without IBD. We performed whole-exome sequencing analyses to characterize the genetic landscape of these tumors. METHODS: We collected colorectal tumor and non-neoplastic tissues from 31 patients with IBD and colorectal cancer (15 with ulcerative colitis, 14 with Crohn's disease, and 2 with indeterminate colitis) and performed whole-exome sequencing analyses of the microdissected tumor and matched nontumor tissues. We identified somatic alterations by comparing matched specimens. The prevalence of mutations in sporadic colorectal tumors was obtained from previously published exome-sequencing studies. RESULTS: Two specimens had somatic mutations in the DNA proofreading or mismatch repair genes POLE, MLH1, and MSH6 and the tumor cells had a hypermutable phenotype. The remaining tumors had, on average, 71 alterations per sample. TP53 was the most commonly mutated gene, with prevalence similar to that of sporadic colorectal tumors (63% of cases). However, tumors from the patients with IBD had a different mutation spectrum. APC and KRAS were mutated at significantly lower rates in tumors from patients with IBD than in sporadic colorectal tumors (13% and 20% of cases, respectively). Several genes were mutated more frequently or uniquely in tumors from patients with IBD, including SOX9 and EP300 (which encode proteins in the WNT pathway), NRG1 (which encodes an ERBB ligand), and IL16 (which encodes a cytokine). Our study also revealed recurrent mutations in components of the Rho and Rac GTPase network, indicating a role for noncanonical WNT signaling in development of colorectal tumors in patients with IBD. CONCLUSIONS: Colorectal tumors that develop in patients with IBD have distinct genetic features from sporadic colorectal tumors. These findings could be used to develop disease-specific markers for diagnosis and treatment of patients with IBD and colorectal cancer.
BACKGROUND & AIMS: A long duration of inflammatory bowel disease (IBD) increases the risk for colorectal cancer. Mutation analysis of limited numbers of genes has indicated that colorectal tumors that develop in patients with IBD differ from those of patients without IBD. We performed whole-exome sequencing analyses to characterize the genetic landscape of these tumors. METHODS: We collected colorectal tumor and non-neoplastic tissues from 31 patients with IBD and colorectal cancer (15 with ulcerative colitis, 14 with Crohn's disease, and 2 with indeterminate colitis) and performed whole-exome sequencing analyses of the microdissected tumor and matched nontumor tissues. We identified somatic alterations by comparing matched specimens. The prevalence of mutations in sporadic colorectal tumors was obtained from previously published exome-sequencing studies. RESULTS: Two specimens had somatic mutations in the DNA proofreading or mismatch repair genes POLE, MLH1, and MSH6 and the tumor cells had a hypermutable phenotype. The remaining tumors had, on average, 71 alterations per sample. TP53 was the most commonly mutated gene, with prevalence similar to that of sporadic colorectal tumors (63% of cases). However, tumors from the patients with IBD had a different mutation spectrum. APC and KRAS were mutated at significantly lower rates in tumors from patients with IBD than in sporadic colorectal tumors (13% and 20% of cases, respectively). Several genes were mutated more frequently or uniquely in tumors from patients with IBD, including SOX9 and EP300 (which encode proteins in the WNT pathway), NRG1 (which encodes an ERBB ligand), and IL16 (which encodes a cytokine). Our study also revealed recurrent mutations in components of the Rho and Rac GTPase network, indicating a role for noncanonical WNT signaling in development of colorectal tumors in patients with IBD. CONCLUSIONS:Colorectal tumors that develop in patients with IBD have distinct genetic features from sporadic colorectal tumors. These findings could be used to develop disease-specific markers for diagnosis and treatment of patients with IBD and colorectal cancer.
Authors: Karsten Schulmann; Yuriko Mori; Victoria Croog; Jing Yin; Andreea Olaru; Anca Sterian; Fumiaki Sato; Suna Wang; Yan Xu; Elena Deacu; Agnes T Berki; James P Hamilton; Takatsugu Kan; John M Abraham; Wolff Schmiegel; Noam Harpaz; Stephen J Meltzer Journal: Gastroenterology Date: 2005-07 Impact factor: 22.682
Authors: Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz Journal: Sci Transl Med Date: 2014-02-19 Impact factor: 17.956
Authors: Chung Wah Wu; Siew Chien Ng; Yujuan Dong; Linwei Tian; Simon Siu Man Ng; Wing Wa Leung; Wai Tak Law; Tung On Yau; Francis Ka Leung Chan; Joseph Jao Yiu Sung; Jun Yu Journal: Clin Cancer Res Date: 2014-04-01 Impact factor: 12.531
Authors: Jun Yu; William K K Wu; Xiangchun Li; Jun He; Xiao-Xing Li; Simon S M Ng; Chang Yu; Zhibo Gao; Jie Yang; Miao Li; Qiaoxiu Wang; Qiaoyi Liang; Yi Pan; Joanna H Tong; Ka F To; Nathalie Wong; Ning Zhang; Jie Chen; Youyong Lu; Paul B S Lai; Francis K L Chan; Yingrui Li; Hsiang-Fu Kung; Huanming Yang; Jun Wang; Joseph J Y Sung Journal: Gut Date: 2014-06-20 Impact factor: 23.059
Authors: Georg Schneditz; Joshua E Elias; Ester Pagano; M Zaeem Cader; Svetlana Saveljeva; Kathleen Long; Subhankar Mukhopadhyay; Maryam Arasteh; Trevor D Lawley; Gordon Dougan; Andrew Bassett; Tom H Karlsen; Arthur Kaser; Nicole C Kaneider Journal: Sci Signal Date: 2019-01-01 Impact factor: 8.192
Authors: Chia Wei Hsu; Mark L Sowers; Willie Hsu; Eduardo Eyzaguirre; Suimin Qiu; Celia Chao; Charles P Mouton; Yuri Fofanov; Pomila Singh; Lawrence C Sowers Journal: Trends Cancer Res Date: 2017